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REGULAR ARTICLE
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Key Points
•Only pDCs among all
human DC subsets re-
act robustly to EBV in-
fection with a distinct
production of type
I IFN subtypes.
• EBV infections limit
pDC activation, and
even exogenous IFN
supplementation or
pDC expansion delays
EBV infection only
transiently.
Infectious mononucleosis, caused by infection with the human gamma-herpesvirus Epstein-
Barr virus (EBV), manifests with one of the strongest CD81 T-cell responses described in
humans. The resulting T-cell memory response controls EBV infection asymptomatically in
the vast majority of persistently infected individuals. Whether and how dendritic cells (DCs)
contribute to the priming of this near-perfect immune control remains unclear. Here we
show that of all the human DC subsets, plasmacytoid DCs (pDCs) play a central role in the
detection of EBV infection in vitro and in mice with reconstituted human immune system
components. pDCs respond to EBV by producing the interferon (IFN) subtypes a1, a2, a5, a7,
a14, and a17. However, the virus curtails this type I IFN production with its latent EBV gene
products EBNA3A and EBNA3C. The induced type I IFNs inhibit EBV entry and the
proliferation of latently EBV-transformed B cells but do not inﬂuence lytic reactivation of the
virus in vitro. In vivo, exogenous IFN-a14 and IFN-a17, as well as pDC expansion, delay EBV
infection and the resulting CD81 T-cell expansion, but pDC depletion does not signiﬁcantly
inﬂuence EBV infection. Thus, consistent with the observation that primary immunodeﬁ-
ciencies compromising type I IFN responses affect only alpha- and beta-herpesvirus
infections, we found that EBV elicits pDC responses that transiently suppress viral
replication and attenuate CD81 T-cell expansion but are not required to control primary
infection.
Introduction
Epstein-Barr virus (EBV) is a common gamma herpesvirus affecting only humans.1 EBV is one of
the most successful viruses, persistently infecting .95% of the adult population. Its success in
establishing persistence in humans is due to a cascade of latent gene expression programs that
allow infected cells to gain access to the long-lived memory B-cell pool.2 The transition of latently
EBV-infected B cells to the virus-associated tumors that express the same latent gene products is
believed to be prevented by cell-mediated immune control3 because immunodeficiencies
affecting cytotoxic lymphocytes predispose for different EBV-positive lymphomas.4-6 Dendritic
cells (DCs) might play a crucial role in priming this protective immune control during primary EBV
infection.7,8
In response to this requirement, the distribution of receptors that recognize pathogen-associated
molecular patterns (PAMPs) on human DCs could have been shaped by successful pathogens
such as EBV during their virus–host coevolution. This action might be one reason why human DCs
Submitted 31 August 2018; accepted 24 February 2019. DOI 10.1182/
bloodadvances.2018025536.
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differ significantly in their PAMP recognition from the mouse.9
Indeed, the Toll-like receptors 7 (TLR7) and TLR9 that recognize
as PAMPs, respectively, viral RNA and double-stranded DNA, as
packaged in herpesviruses, have peculiar distributions. They are
primarily expressed by B cells and plasmacytoid DCs (pDCs) in
humans, whereas they are present on nearly all DC subsets in
mice.9,10 This differential response by DCs to TLR stimulation
can also be observed in mice with human immune system
components (huNSG mice) after reconstitution with CD341
hematopoietic progenitor cells.11,12 These in vivo models allow
the interrogation of mouse and human DCs in parallel upon
injection of TLR stimuli. TLR7 stimulation elicits efficient type I
interferon (IFN) production by human pDCs but nearly no
interleukin-12 (IL-12) production by human conventional DCs
(cDCs).11 In contrast, mouse DC compartments react with both
cytokines to TLR7 stimulation. Similarly, bacterial cell wall
components such as TLR4 agonists elicit both type I IFN and
IL-12 by mouse DCs but are not efficiently detected by human
pDCs or cDCs due to low or absent TLR4 expression. The human
DC compartments of huNSG mice can therefore be used to
interrogate innate immune detection of EBV by human DCs to
further characterize the antigen-presenting cells that are involved in
the priming of the near-perfect immune control of this tumor virus.
As one of these human DC compartments, pDCs respond primarily
with type I IFN to viral infections. Type I IFNs are a pleiotropic family
of cytokines with important functions in eliciting antiviral immune
responses within the host. Type I IFNs consist of 12 distinct IFN-a
subtypes, IFN-b, IFN-e, IFN-k, and IFN-v.13 All IFN-a subtypes lack
introns, and their protein length varies between 161 and 167 amino
acids. Their protein sequences are highly conserved, with 75% to
99% amino acid sequence identity.14,15 They all bind to the IFN-a/b
receptor (IFNAR) receptor, although binding affinity to the receptor
subunits IFNAR1 and IFNAR2 differs between subtypes.16 The
activation of distinct signaling cascades may occur in a subtype-
specific manner,17 possibly due to different binding affinities,
cell type specificities, the microenvironment, and timing or
preconditioning of signaling pathways.18,19 These factors ulti-
mately result in specific patterns of IFN-stimulated genes (ISGs)
induced by the individual IFN-a subtypes. This action in turn
explains their distinct antiviral and immunomodulatory properties
in different viral infections.20-26 However, the biological role of
individual IFN-a subtypes during EBV infection has not been
studied thus far, partly due to lack of a suitable in vivo infection
model.
After EBV infection in vivo, we found that IFN-a responses
predominated over those of IL-12, suggesting that pDCs were
the main DC subset responding to EBV infection. We further found
a specific IFN-a signature elicited by EBV infection characterized by
robust production of IFN-a1, IFN-a2, IFN-a5, IFN-a7, IFN-a14,
and IFN-a17. Although type I IFN responses were not required for
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Figure 1. EBV infection elicits type I IFN production in PBMCs in a pDC-dependent manner. Total PBMCs were exposed to EBV, CpG C, Poly I:C, or R848 at the
indicated concentrations, and culture supernatants were collected after 18 to 24 hours and analyzed for cytokine production according to enzyme-linked immunosorbent assay.
IFN-a (A) and IL-12p40 (B) content was measured. (C) PBMCs were inoculated with wild-type EBV (wt), EBNA3A-deficient EBV (3aKO), or EBNA3C-deficient EBV (3cKO),
and IFN-a production was measured. MOI 0.005, n 5 5; MOI 0.05, n 5 7; and MOI 0.25, n 5 9. (D) Total PBMCs were compared with pDC-depleted PBMCs. MOI 0.005,
n 5 2; MOI 0.05, n 5 4; and MOI 0.25, n 5 2. Paired Student t tests were used for all graphs.
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EBV-driven T-cell expansion, IFN-a was capable of limiting EBV
entry into B cells in vitro and delaying EBV infection in vivo. These
studies suggest that pDCs are part of the innate immune response
to EBV but that EBV has developed countermeasures against type I
IFN production, including expression of the latent gene products
EBNA3A and EBNA3C.
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Figure 2. EBV elicits IFN-a1, IFN-a2, IFN-a5, IFN-a7, IFN-a14, and IFN-a17 preferentially after pDC stimulation in PBMCs. (A) Relative messenger RNA (mRNA)
levels of IFN-a subtypes were measured in isolated pDCs exposed to EBV or R848 for 1 hour (n 5 2) or to EBV (n 5 4 for IFN-a16 and IFN-a17; n = 5 for the other IFN-a
subtypes) or CpG C (n 5 2) for 5 hours. (B) Relative mRNA levels of IFN-a subtypes were measured on total PBMCs or pDC-depleted PBMCs 16 hours after infection (n 5 3).
(C) Total PBMCs were exposed to wild-type EBV (wt), EBNA3A-deficient EBV (3aKO), or EBNA3C-deficient EBV (3cKO) for 24 hours. Relative mRNA levels of the ISGs MxB,
STAT1, IFIT3, and OAS2 were measured by using quantitative real-time polymerase chain reaction. (D) Total PBMCs were exposed to class C CpG ODN 2395 (CpG C) or R848
for 24 hours. Relative mRNA levels of the ISGs were assessed as in panel D. Paired Student t tests were used for statistical analyses. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and succinate dehydrogenase complex flavoprotein subunit A (SDHA) were used to normalize mRNA levels.
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Materials and methods
EBV virus purification
EBV B95-8 was produced from EBNA3A knock-out (3aKO),
EBNA3C knock-out (3cKO), or wild-type bacterial artificial
chromosomes maintained in human embryonic kidney HEK293
cells, as described elsewhere.27 To calculate Raji green units (RGU),
the green fluorescent protein (GFP)–expressing viruses were titrated
on Raji cells (ATCC) in serial dilution, and the GFP-expressing cells
were analyzed by flow cytometry 2 days later.
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Figure 3. IFN-a6, IFN-a14, IFN-a16, and IFN-a17 inhibit EBV entry and B-cell transformation into LCLs. (A) Raji cells were exposed to EBV and the indicated
concentrations of IFN-a subtypes for 48 hours. GFP expression as a measure of EBV entry was determined by using flow cytometry, and the ratios of EBV plus IFN-a to EBV
only are shown in the graph. Statistical analysis was done on raw data (percent GFP-positive cells), and paired Student t tests were applied. IFN-a6: n 5 3. IFN-a14: 100 ng/mL,
n 5 6; 10 ng/mL, n 5 15; 1 ng/mL, n 5 12. IFN-a16: 100 ng/mL, n 5 3; 10 ng/mL and 1 ng/mL, n 5 5. IFN-a17: 100 ng/mL and 10 ng/mL, n 5 4; 1 ng/mL, n 5 1. (B) Isolated
B cells or total PBMCs were exposed to EBV in the presence or absence of the IFN-a subtypes for 6 days, and proliferation was measured by CellTrace Violet (CTV) dilution.
Statistical analysis was performed on raw data (percent proliferating cells), and paired Student t tests were applied. B cells: IFNa6, n 5 2; IFN-a14, n 5 16; IFN-a16, n 5 4;
IFN-a17, n 5 2. PBMCs: IFN-a6, n 5 2; IFN-a14, n 5 16; IFN-a16, n 5 6; IFN-a17, n 5 2. (C) Proliferation of isolated B cells was also measured after 8 days of culture by
pulsing the cells with [3H]-thymidine for 16 hours and thereafter measuring [3H]-thymidine incorporation (n 5 2). In the lower graph, n 5 2 for IFN-a6 and n 5 4 for IFN-a14. (D)
The proliferation of LCLs in the presence or absence of IFN-a14 was measured after 4 days by thymidine incorporation (n 5 3). Paired Student t tests were applied.
(E) Resistance of lytic EBV reactivation against IFN-a subtypes was shown by using AKBM cells (n 5 5 for PBS, n 5 4 for IFN-a6 and IFN-a14, n 5 3 for IFN-a16
and IFN-a17).
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Isolation of cell subsets from peripheral blood
mononuclear cells
Peripheral blood mononuclear cells (PBMCs) from healthy donors
were isolated by density gradient centrifugation on Ficoll-Paque
Premium (GE Healthcare). pDCs and B cells were isolated with
BDCA-4 and CD19 microbeads, respectively, by using an Auto-
MACS pro (Miltenyi Biotec GmbH). For the pDC-depleted fractions,
BDCA-4 microbeads were used, and the most stringent AutoMACS
depletion program (deplete 025) was applied.
Recombinant IFN-a subtypes and inhibition assays
The recombinant IFN-a subtypes used in this study were produced
and purified as previously described.24 Raji, Ramos, or primary
B cells were distributed in 96 well plates and exposed to IFN-a
subtypes and EBV at the indicated concentrations and multiplicities
of infection (MOIs) for 48 hours, and viral entrance into the cell
nucleus was detected by GFP expression according to flow
cytometry. B-cell or EBV-transformed lymphoblastoid cell line (LCL)
proliferation was measured by using the CellTrace Violet Cell
Proliferation Kit (Thermo Fisher Scientific), following the manufac-
turer’s instructions. Alternatively, proliferation was measured by
thymidine incorporation: after 8 days of culture, [3H]thymidine
(1 mCi/well) was added for the last 16 hours before the cells
were harvested, and the level of [3H]thymidine incorporation was
measured by using a 1450 MicroBeta Plus liquid scintillation
counter (PerkinElmer).
TLR ligands
Class C CpG ODN 2395 (CpG C) was purchased from InvivoGen,
R848 from Enzo Life Sciences, and Poly (I:C) from InvivoGen.
Mice
NOD-scid gc
null (NSG) mice were obtained from The Jackson
Laboratory, and huNSG mice were generated as previously
described.27-29 Newborn NSG mice (1-5 days old) were irradiated
with 1 Gy and reconstituted after 5 to 7 hours by intrahepatic
injection of 1 to 3 3 105 CD341 human fetal liver–derived
hematopoietic progenitor cells (Advanced Bioscience Resources).
Twelve weeks later, the reconstitution of human immune system
components in the peripheral blood of the huNSG mice was
analyzed by using flow cytometry. For cell preparations, spleens
were mechanically disrupted and filtered by using a 70-mm cell
strainer before erythrocyte lysis. Lymph nodes were mechanically
disrupted and filtered through a 70-mm cell strainer. Bone marrow
cells were flushed from excised tibia and femurs or isolated via
centrifugation. Whole blood was treated by 2 to 3 rounds of
erythrocyte lysis. All animal protocols were approved by the
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Figure 4. EBV infection elicits type I IFN production in huNSG mice. huNSG mice were infected with 5 3 105 RGU EBV, and blood samples were analyzed 18 hours
postinfection. IFN-a (A) or IL-12p40 (B) production was measured in the serum by enzyme-linked immunosorbent assay (PBS, n 5 11; EBV, n 5 12). (C) IFN-a levels
were compared in the serum of huNSG mice that were PBS treated (n 5 6) or infected with either 5 3 105 RGU of wild-type EBV (wt, n 5 6), EBNA3A-deficient EBV
(3aKO, n 5 6), or EBNA3C-deficient EBV (3cKO, n 5 8). (D) ISG induction was measured in blood leukocyte lysates by using quantitative real-time polymerase chain
reaction. n 5 8 for PBS; n 5 9 for EBV. Unpaired Student t tests were applied.
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Figure 5. Type I IFN injection transiently controls viral loads and attenuates CD81 T-cell expansion after EBV infection in huNSG mice. (A) huNSG mice were
treated with either PBS, IFN-a14, or IFN-a17 for 15 consecutive days, starting 1 day before infection with 1 3 105 RGU EBV (schematic depiction). (B) Viral DNA loads were
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Cantonal Veterinary Office Zurich (148/2011, ZH209/2014, and
ZH159/17).
EBV infection and treatment of mice
huNSGmicewere injected intraperitoneally (IP) with 13 105 RGUor
5 3105 RGU EBV wild-type, 5 3 105 RGU 3aKO, or 5 3 105 RGU
3cKO. For IFN-a treatment, recombinant IFN-a subtypes IFN-a14
or IFN-a17 (8000 U per mouse) were injected IP for 14 consecutive
days, starting 1 day before EBV infection. For DC expansions, mice
were injected IP with 10 mg of recombinant human Fms-related
tyrosine kinase 3 ligand (FLT3L, generously provided by Amgen
Inc.) daily for 5 to 8 consecutive days before EBV infection. For
pDC depletions, mice were injected IP with 3 doses of 30 mg/kg
anti–CD303-LFB (a-CD303) as per manufacturer’s recommen-
dations (generously provided by LFB Biotechnologies). Anti–
CD303-LFB is the humanized version of chimeric 122A2 antibody
previously described.30 Depletion efficiency was monitored according
to flow cytometric analysis of peripheral blood samples beginning
before EBV infection and weekly thereafter. At experimental termi-
nation, depletion was further assessed in blood, spleen, bone
marrow, and lymph nodes.
Assessment of EBV viral titer in blood and spleen
EBV viral loads were measured as previously described.27,29,31
Enzyme-linked immunosorbent assay
IFN-a Pan and IL-12p40 enzyme-linked immunosorbent assay kits
were purchased from Mabtech AB, and assays were performed
according to the manufacturer’s recommendations.
Statistical analysis
Statistical analyses were performed by using Prism software
(GraphPad Software). Paired Student t tests, unpaired Student
t tests, or 2-tailed Mann-Whitney U tests were used as indicated.
Differences with P , .05 were considered statistically significant
and are displayed in the figures.
Results
EBV infection is mainly sensed by pDCs via type I IFN
production in human leukocytes
To evaluate innate immune detection of EBV by human leuko-
cytes, we characterized production of the pDC- or cDC-specific
signature cytokines IFN-a (total IFNa, including all subtypes) and
IL-12, respectively,32,33 in human PBMCs after EBV infection.
Eighteen to 24 hours after infection with the B95-8 strain of
EBV at different MOIs, substantial IFN-a production could be
measured, with levels similar to, or exceeding, stimulation with
the TLR9 agonist CpG, the TLR3 agonist Poly I:C, and the TLR7/
8 agonist R848 (Figure 1A). IFN-b was also produced but at
10-fold lower levels (supplemental Figure 1C). In contrast, only
minimal IL-12p40, with concentrations 10-fold lower than R848
stimulation, could be detected (Figure 1B). In good agreement
with previous findings that the nuclear antigen 3C of EBV
(EBNA3C) interferes with IFN regulatory factors,34 we ob-
served that PBMCs produced fivefold higher IFN-a levels in
response to infection with EBNA3A- and EBNA3C-deficient
viruses (3aKO and 3cKO) (Figure 1C). IFN-a production by
wild-type, 3aKO, and 3cKO viruses was dependent on pDCs
because their depletion reduced IFN-a concentrations to
background levels upon EBV infection (Figure 1D; supplemen-
tal Figure 1A). Interestingly, and in contrast to IFN-a produc-
tion, the low levels of IL-12p40 production were further
decreased in the absence of EBNA3A or EBNA3C (supple-
mental Figure 1B). Regardless of the presence or absence of
EBNA3A or EBNA3C, EBV infection did not influence pDC
viability (supplemental Figure 1D). These findings support the
notion that pDCs are the primary DC subtype responding to
initial EBV infection.
pDCs preferentially produce IFN-a1, IFN-a2, IFN-a5,
IFN-a7, IFN-a14, and IFN-a17 after EBV infection of
human leukocytes
Recent studies have identified significant differences in the
efficacy of IFN-a subtypes during hepatitis B virus, HIV, and
simian immunodeficiency virus infections.35 We therefore
addressed which human IFN-a subtypes were elicited upon
exposure of pDCs (Figure 2A) or PBMCs (Figure 2B) to EBV.
For this purpose, IFN-a subtype transcription was character-
ized in purified pDCs at 1 and 5 hours post-EBV exposure or
incubation with R848 or CpG. At 5 hours, EBV elicited mainly
IFN-a1, IFN-a2, IFN-a5, IFN-a7, IFN-a14, and IFN-a17.
Expression of IFN-a5 and IFN-a17 was further observed
already at 1 hour postexposure when transcript levels were
still very low. In contrast, IFN-a production in response to R848
was dominated by IFN-a2 and IFN-a14, whereas CpG elicited
mainly IFN-a17. The same IFN-a subtype pattern in response to
EBV was also observed in infected PBMCs 16 hours after EBV
exposure and, likewise, was strictly pDC dependent. As a
confirmation of EBV-dependent IFN-a transcription, we ana-
lyzed messenger RNA levels of the ISG myxovirus resistance
protein B (MxB),36 signal transducer and activator of transcrip-
tion 1 (STAT1),37 IFN-induced protein with tetratricopeptide
repeats 3 (IFIT3),38 and 29-59-oligoadenylate synthetase
2 (OAS2).39 All of these ISGs were efficiently induced by
EBV exposure, and both IFIT3 and OAS2 exhibited a trend
toward higher induction by EBNA3A- and EBNA3C-deficient
viruses (Figure 2C). ISG transcription upon EBV exposure
reached similar or higher levels compared with CpG and R848
stimulation (Figure 2D). Thus, EBV sensing by pDCs results in
the preferential production of IFN-a1, IFN-a2, IFN-a5, IFN-a7,
IFN-a14, and IFN-a17.
Figure 5. (continued) determined by quantitative polymerase chain reaction in the blood over time and in the spleen at week 5. (C) Spleen weight was measured upon
euthanization at week 5. (D) The ratio of CD8/CD4 T cells in the blood of huNSG mice was determined by using flow cytometry and monitored over time. Total CD8 and CD4
T-cell counts were determined at week 5. In the summary graphs over time (B,D), data are presented as the mean 6 standard error of the mean (SEM). (E) The ratio of CD8/CD4
bone marrow T cells was determined by using flow cytometry. (F) The ratio of CD8/CD4 splenic T cells and total CD8 and CD4 T-cell numbers per spleen was determined by using
flow cytometry at week 5. Data were pooled from 5 independent experiments (PBS, n 5 20; IFN-a14, n 5 15; IFN-a17, n 5 15), and unpaired Student t tests were used.
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IFN-a subtypes inhibit EBV entry and proliferation
of latently EBV-infected B cells but not lytic
EBV reactivation
We next assessed the ability of various IFN-a subtypes to modulate
different stages of the EBV life cycle.40 We chose the 2 IFN-a
subtypes that were abundantly produced during EBV infection of
human leukocytes, IFN-a14 and IFN-a17, and 2 that were
subdominant, IFN-a6 and IFN-a16. We first tested to what extent
titrated doses of the IFN-a subtypes, including 10 ng/mL (which we
detected during EBV stimulation of PBMCs), were able to inhibit
EBV entry (Figure 3A). For this purpose, recombinant EBV viruses
encoding GFP were used to infect the Raji or Ramos Burkitt
lymphoma cell lines or primary human B cells. GFP expression as a
measure of viral DNA delivery to the nucleus was evaluated in the
presence of 1, 10, and 100 ng/mL of IFN-a6, IFN-a14, IFN-a16, or
IFN-a17. All IFN-a subtypes, including IFN-a14, were able to inhibit
GFP expression in a dose-dependent manner after EBV entry into
Raji cells, as well as into Ramos and primary human B cells
(supplemental Figure 2A). B-cell viability was not influenced by this
treatment (supplemental Figure 2B).
Furthermore, B-cell proliferation as a result of latent EBV infection
after EBV entry was measured by dilution of the CellTrace Violet
fluorescent dye or radioactive thymidine incorporation. This prolif-
eration was inhibited in a dose-dependent manner by some IFN-a
subtypes, including IFN-a14 (Figure 3B-C). Finally, the proliferation
of established B-cell lines transformed by latent EBV infection,
LCLs, was also inhibited by 10 ng/mL of recombinant IFN-a14
(Figure 3D). In contrast, lytic EBV reactivation upon B-cell receptor
cross-linking on the Akata Burkitt lymphoma cell–derivative AKBM
was not altered by the tested IFN-a subtypes (Figure 3E). All of
the tested IFN-a subtypes stimulated similar STAT1 phosphoryla-
tion, downstream of the type I IFN receptor, as measured by using
intracellular flow cytometry or Western blotting (supplemen-
tal Figure 3). These studies indicate that EBV entry and latent
EBV-driven B-cell expansion can be partially inhibited by different
IFN-a subtypes, including IFN-a14, produced in response to EBV
infection, whereas lytic EBV reactivation is not affected by type I
IFNs.
EBV infection elicits type I IFN production in mice with
reconstituted human immune system components
To extend these in vitro studies to EBV infection in vivo, we infected
NOD-scid gc
2/2 mice that had been reconstituted with human
immune system compartments by neonatal intrahepatic injection of
human CD341 hematopoietic progenitor cells28 with 53 105 RGU
of recombinant EBV viruses. Eighteen hours after infection, we
detected;1 ng/mL of total IFN-a and not detectable or,10 pg/mL
of IFN-b in the peripheral blood of infected, but not uninfected,
mice (Figure 4A; supplemental Figure 4A). No significant increase
in IL-12 production could be detected at 18 and 72 hours after
infection (Figure 4B), mirroring the in vitro findings in PBMCs
(Figure 1A-B). Although unchanged IL-12p40 concentrations
could be detected, IL-12p70 levels were below the detection limit
(data not shown). An increase in IFN-a production could also be
detected upon in vivo infection with EBNA3A- and EBNA3C-
deficient viruses (Figure 4C). However, IL-12 production was not
altered in the absence of EBNA3A or EBNA3C. Confirming the
IFN-a induction, an increase in ISG transcription was observed
after EBV infection, which reached statistical significance for
MxB and STAT1 (Figure 4D). These observations suggest that
EBV infection elicits IFN-a, but not IL-12, production in huNSG
mice.
Type I IFN injection transiently attenuates viral loads
and CD81 T-cell expansion after EBV infection in vivo
After IFN-a detection upon EBV infection, we investigated whether
injections of exogenous IFN-a influenced EBV infection of huNSG.
Mice were injected daily with 8000 U of IFN-a14 or IFN-a17, or
phosphate-buffered saline (PBS) as a control, beginning 1 day
before infection with EBV. Blood viral loads and peripheral T-cell
responses were monitored weekly over the course of infection
(Figure 5A). Viral loads were reliably detectable in peripheral blood
of huNSG mice beginning 3 weeks’ postinfection.41 At this time point,
reduced viral loads were observed in peripheral blood of IFN-a–treated
animals compared with PBS control animals. However, at weeks
4 and 5 postinfection, peripheral viral loads were similar between
the treated and untreated groups (Figure 5B). Nevertheless, spleen
weight was significantly lower in EBV-infected, IFN-a–treated
animals at the time of euthanization (Figure 5C). Although only
data from IFN-a14–treated animals reached statistical significance,
similar effects on viral loads and spleen weighs were observed in
both IFN-a14– and IFN-a17–treated groups.
Spleen size increases upon EBV infection are due to EBV-
transformed B-cell proliferation but mostly due to expanding
CD81 T cells.41 We therefore analyzed CD81 T-cell expansion
in response to EBV infection of huNSG mice after IFN-a14 or
IFN-a17 treatment. CD81 T-cell expansion after EBV infection
was similar in spleen and blood in the absence or presence of an
HLA-A2 transgene in huNSG mice (supplemental Figure 4B).
In IFN-a14–treated animals, reduced blood viral titers were
observed at week 3 postinfection, with a corresponding reduc-
tion in CD81 T-cell expansion in the blood at week 4 (Figure 5D).
A similar trend was present in IFN-a14– and IFN-a17–treated
animals at week 5 postinfection, which was further detected
in the bone marrow and spleen at euthanization (Figure 5E-F).
Decreased CD81 T-cell expansion further correlated with
diminished spleen size in EBV-infected, IFN-a–treated huNSG
mice compared with nontreated, infected animals but did
not significantly alter CD81, EBNA21, or CD201 cell distribu-
tion in splenic tissue sections (supplemental Figure 4C). Taken
together, these experiments show that the presence of
IFN-a early in infection can limit EBV infection and/or viral
replication and may reduce CD81 T-cell expansion as a
consequence.
EBV infection may redistribute pDCs in vivo, which,
upon expansion, transiently control viral loads
To characterize which DC subpopulations respond during EBV
infection of huNSG mice, we monitored pDCs and cDCs after
intraperitoneal inoculation with 105 RGU of EBV. We observed that
percentages and total numbers of pDCs and cDCs dropped in the
peripheral blood upon EBV infection (Figure 6A). Although pDC
and cDC percentages also decreased in the spleen after infection,
presumably due to lymphocyte expansion, total splenic DC numbers
were unchanged or perhaps slightly increased. The decreased
percentages and total numbers of pDCs in the peripheral blood
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Figure 6. EBV infection decreases pDCs in the blood of huNSG mice. (A) The DC subsets, pDCs (huCD451, HLA-DR1, CD3CD19CD56–, CD14CD16–, CD11c–, and
BDCA-21), and cDCs (huCD451, HLA-DR1, CD3CD19CD56–, CD14CD16–, and CD11c1) were examined by using flow cytometry (see supplemental Figure 5A for gating
strategy) in the blood and spleens of huNSG mice, 5 to 6 weeks after infection with 1 3 105 RGU EBV IP or PBS treatment as a control. The DC frequencies of huCD451
cells (n 5 16-21, from 6 individual cohorts) and total numbers (n 5 12-15, from 5 individual cohorts) of the DC subsets were determined. (B) pDC frequencies (n 5 16-20,
paired Student t test) and total numbers (n 5 4-11, unpaired Student t test) were measured over time. (C) FLT3L (20 mg per mouse) or PBS was injected IP into huNSG mice
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Figure 6. (Continued) for 5 or 8 consecutive days to expand the DC compartment. The DC frequencies of huCD451 cells, their fold increase, and total DC numbers in the
blood (PBS, n 5 15; FLT3L, n 5 20), as well as the total DC number in the spleen (PBS, n 5 9; FLT3L, n 5 13), were assessed for pDCs, cDCs, and the BDCA-11 or
BDCA-31 cDC subsets. (D) After 8 IP injections of FLT3L, huNSG mice from one cohort were infected with 1 3 105 RGU EBV and thereafter monitored for T-cell expansion
and EBV viral load in the blood (schematic depiction). (E) EBV viral load was determined at weeks 3 to 5 in the blood and at week 5 in the spleen. (F) Spleen weight was
determined at week 5, and unpaired Student t tests were applied. (G) Conversion of the CD8/CD4 T-cell ratio was monitored weekly in the blood and in the spleen at week 5.
Total CD81 and CD41 T-cell numbers per milliliter whole blood and per spleen at week 5 are depicted. In the summary graphs over time (E,G), data are presented as the
mean 6 SEM (PBS, n 5 2; FLT3L, n 5 3; EBV 1 PBS, n 5 4; EBV 1 FLT3L, n 5 4).
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Figure 7. pDC depletion alters neither viral load nor T-cell expansion in EBV-infected huNSG mice. (A) pDCs were depleted in huNSG mice by using 3 injections
of a CD303-specific antibody (anti–CD303-LFB; designated a-CD303 throughout the figures) before infection with 1 3 105 RGU EBV. Alternatively, PBS or isotype antibody
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were detectable as early as 3 weeks’ postinfection and were
maintained for the duration of infection (Figure 6B), whereas no loss
of pDC viability could be detected during EBV infection (supple-
mental Figure 5B), suggesting that blood pDCs redistribute to
secondary lymphoid tissues after EBV infection.
We further analyzed the effect of therapeutic DC expansion on EBV
infection in huNSGmice. For this purpose, we injected recombinant
FLT3L, a cytokine essential for efficient DC development,42 before
EBV infection (Figure 6D). FLT3L treatment significantly expanded
both pDCs (up to fivefold) and cDCs (up to 10-fold) in huNSGmice
(Figure 6C). The flow cytometric gating strategy for the quantifica-
tion of these DC populations, as well as the CD1c1 (BDCA-11) and
CD1411 (BDCA-31) cDC subsets, is shown in supplemental
Figure 5A and is similar to our previous assessment.11 Consistent
with recombinant IFN-a subtype injections, FLT3L-mediated DC
expansion resulted in delayed EBV infection with reduced viral titers
at week 3 after virus injection (Figure 6E). Furthermore, spleen
weights of DC-expanded and EBV-infected huNSG mice were
reduced at the time of euthanization (Figure 6F). This reduction in
spleen size was likely also the result of decreased CD81 T-cell
expansion, detectable in the peripheral blood 4 weeks’ post-
infection and in the spleen at euthanization (Figure 6G). Accord-
ingly, CD81 T-cell expansion was found to correlate with viral
loads in the spleen, and the drop in DC frequency with increased
viral loads in the spleen most likely resulted from the significant
CD81 T-cell expansion after EBV infection (supplemental
Figure 6A). No differences in viral loads, CD81 T-cell, pDC, and
cDC frequencies and total numbers were found in EBV-induced
lymphoma-bearing mice vs tumor-free mice (supplemental
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Figure 7. (Continued) treatment was used as controls (schematic depiction). (B) Percentage of pDCs was determined by flow cytometry gating on HLA-DR1, CD19–, CD3–,
NKp46–, CD14CD16–, CD11c–, CD1231, and CD41 cells (supplemental Figure 7A). Before treatment and at day 0, after 2 a-CD303 injections, the pDC depletion efficiency
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Figure 6B). Thus, DCs may redistribute to secondary lymphoid
organs during EBV infection, and expanding them therapeutically
with FLT3L before EBV infection leads to a transient improvement in
viral immune control.
pDC depletion does not alter EBV infection or CD81
T-cell expansion
These gain-of-function experiments suggested that improved pDC-
mediated IFN-a production delays EBV infection in vivo. However,
the reconstituted human immune system compartments of huNSG
mice contain ;1% pDCs, a frequency similar to that of human
blood.43 We therefore characterized whether this physiological
level of pDCs is sufficient to execute innate immune control of EBV
infection and influence adaptive T-cell responses to the virus.
Accordingly, we depleted pDCs with a CD303 (BDCA-2)-specific
antibody (anti–CD303-LFB) before and 1 day after EBV infection
(Figure 7A). This treatment efficiently removed pDCs from the blood
of huNSGmice (Figure 7B) and further abolished IFN-a production,
and even the minimal IL-12 production, occurring in response to
EBV infection (Figure 7C). It also significantly diminished ISG
transcription for MxB and STAT1 (supplemental Figure 7B). This
depletion persisted in the blood until euthanization and was also
detectable in spleen and lymph nodes but not in the bone marrow
(Figure 7D-E). cDCs were not affected by the CD303-specific pDC
depletion (Figure 7F). The pDC depletion did not affect EBV viral
loads longitudinally in blood or spleen at euthanization (Figure 7G).
Furthermore, spleen weights were not significantly altered in EBV-
infected, pDC-depleted huNSG mice (Figure 7H). Accordingly,
CD81 T-cell expansion and activation, as well as natural killer cell
frequencies, were comparable with and without pDC depletion in
blood, lymph nodes, bone marrow, and spleen (Figure 7I; supple-
mental Figure 7C-F). These findings suggest that pDC expansion
and IFN-a injection transiently improve immune control of EBV but
that the physiological pDC response to EBV infection is not
sufficient to alter infection and immune control of the virus in vivo.
Discussion
Our study found that of all DC compartments, pDCs reacted most
robustly to EBV infection of PBMCs in vitro and of huNSG mice in
vivo. They preferentially produced IFN-a1, IFN-a2, IFN-a5, IFN-a7,
IFN-a14, and IFN-a17 after EBV infection, and this type I IFN
production was suppressed by the latent EBV antigens EBNA3A
and EBNA3C. IFN-a subtypes inhibited EBV entry and proliferation
but not lytic reactivation of EBV. Furthermore, administration of
exogenous IFN-a14 or IFN-a17 to huNSG mice delayed EBV
infection but did not significantly influence the viral load set point.
Although EBV infection activates pDCs after infection of huNSG
mice and leads to their loss from blood in both huNSG mice and
humans during primary EBV infection,44,45 their depletion does not
influence viral titers. Therefore, pDCs detect EBV and participate in
the innate immune response to this tumor virus but do not
significantly influence the outcome of its infection.
These data are in good agreement with previous in vitro studies
that described innate immune recognition of EBV via TLR9 of
pDCs.46-49 TLR9 preferentially detects nonmethylated CpG motifs
in viral DNA.10 This recognition targets the linear viral DNA in virus
particles.47 However, after B-cell infection with EBV, viral DNA
rapidly circularizes into an episome, which is then heavily methylated
and thereby presumably invisible to innate immune detection.50 In
addition, TLR2 and TLR3, which are preferentially expressed by
cDCs and myeloid cells, have been implicated in EBV detection.51-53
However, we detected very little direct cDC activation as measured
by IL-12 production. Moreover, primarily hairpin structures in
EBV-encoded small RNAs have been suggested to stimulate both
TLR3 and RIG-I as endosomal and cytosolic PAMP receptors
for double-stranded RNA,53,54 but we have previously detected
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no significant changes in EBV infection and associated T-cell
expansions in huNSG mice after infection with EBV-encoded
small RNA–deficient EBV.55 Thus, EBV readily activates pDCs
and pDC-mediated type I IFN production but only marginally
stimulates cDCs.
Despite their activation, depletion of pDCs resulted in no significant
changes in EBV infection and immune control in huNSG mice in
the present study. These findings are also mirrored by primary
immunodeficiencies that affect the type I IFN pathway, including
mutations in STAT1 and TYK2 that compromise type I IFN receptor
signaling, or in UNC-93B and NEMO that compromise endosomal
TLR signaling.56-59 Affected individuals are primarily susceptible to
alpha- and beta-herpesvirus infections, including herpes simplex
encephalitis, but rarely experience EBV-associated diseases.
Similarly, IL-12 and IL-12 receptor mutations, resulting in diminished
IFN-g production during viral infections, do not predispose for
EBV-associated diseases but are clinically characterized primarily
as Mendelian susceptibility to mycobacterial disease.56 Supporting
the notion that IFNs have only transient effects on EBV infection,
viral transformation of B cells is only sensitive during the first 24
hours to type I IFN and to type II IFNs for up to 3 weeks, whereas
LCLs seem to be less sensitive to both IFN classes.60 In good
agreement with this, we find little IL-12 production to drive IFN-g
production and no significant alterations of EBV infection of huNSG
mice after pDC depletion, as the main type I IFN source. This
scenario obviously begs the question how efficient cell-mediated
immune control of EBV is established, which protects most
persistently infected individuals from lymphomagenesis. We and
others have assumed that these responses need to be primed by
DCs before efficient expansion by EBV-transformed B cells.7,61
However, the absence of efficient cDC maturation during EBV
infection and the limited effects of pDC depletion on viral loads and
antiviral T-cell responses force us to reconsider this notion.
Similarly, future studies might need to reevaluate the T-cell priming
potential of EBV-infected B cells in vivo.
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